Table 1.
Baseline characteristics of the patients
| All (n = 832) | CVD cohort (n = 618) | P‐value CVD cohort vs all | Mortality cohort (n = 646) | P‐value Mortality cohort vs all | |
|---|---|---|---|---|---|
| Men (%) | 684 (82.2) | 501 (81.2) | 0.63 | 524 (81.1) | 0.59 |
| Age (years) | 54.5 ± 9.9 | 54.4 ± 9.9 | 0.81 | 54.7 ± 10.0 | 0.68 |
| Duration of diabetes (years) | 5.5 ± 6.6 | 5.5 ± 6.6 | 0.85 | 5.7 ± 6.6 | 0.54 |
| BMI (kg/m2) | 23.6 ± 3.4 | 23.4 ± 3.3 | 0.35 | 23.4 ± 3.3 | 0.35 |
| HbA1c (%) | 8.0 ± 1.7 | 8.1 ± 1.7 | 0.20 | 8.1 ± 1.7 | 0.15 |
| HbA1c (mmol/mol) | 64 ± 18 | 65 ± 19 | 0.20 | 65 ± 19 | 0.15 |
| SBP (mmHg) | 132.8 ± 20.7 | 131.4 ± 19.2 | 0.19 | 131.8 ± 19.4 | 0.30 |
| DBP (mmHg) | 77.5 ± 12.5 | 76.8 ± 11.8 | 0.29 | 76.8 ± 11.8 | 0.30 |
| TC (mmol/L) | 5.46 ± 1.00 | 5.47 ± 0.98 | 0.80 | 5.48 ± 0.99 | 0.62 |
| HDL‐C (mmol/L) | 1.28 ± 0.34 | 1.28 ± 0.34 | 0.79 | 1.28 ± 0.34 | 0.93 |
| eGFR (mL/min/1.73 m2) | 80.6 ± 19.0 | 81.1 ± 19.4 | 0.62 | 80.9 ± 19.5 | 0.73 |
| Current smoker | 350 (42.1) | 265 (42.9) | 0.76 | 275 (42.6) | 0.85 |
| Alcohol intake | 627 (75.5) | 469 (75.9) | 0.85 | 485 (75.1) | 0.87 |
| Oral antidiabetic agents† | 333 (40.0) | 251 (40.6) | 0.82 | 267 (41.3) | 0.61 |
| Insulin‡ | 102 (12.3) | 84 (13.6) | 0.45 | 91 (14.1) | 0.30 |
| Antihypertensive agents | 174 (20.9) | 123 (19.9) | 0.64 | 140 (21.7) | 0.72 |
| Lipid‐lowering agents | 91 (10.9) | 61 (9.9) | 0.51 | 69 (10.7) | 0.88 |
Values are numbers (percentages) or means ± standard deviation. †Excludes patients treated with oral antidiabetic agents and insulin. ‡Includes patients treated with oral antidiabetic agents and insulin. BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, glycosylated hemoglobin; HDL‐C, high‐density lipoprotein cholesterol; SBP, systolic blood pressure; TC, total cholesterol.